WuXi Biologics Enters Agreement with Candid Therapeutics on Trispecific T-cell Engager
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today, a new partnership with Candid Therapeutics,
Read more